The trio of positive studies means that AZ is in pole position to bring an anti-IL-33 drug to market for COPD, after some ...
Lung transplantation is increasingly emerging as a lifesaving solution for patients suffering from critical respiratory ...
AFM can identify unique nanomechanical fingerprints in pulmonary fibrosis, aiding in diagnosis, staging, and monitoring treatment efficacy. Current PF treatment efficacy varies due to challenges in ...
Mepolizumab targets IL-5, addressing eosinophilic inflammation in 20%-40% of COPD patients, marking its fifth US indication. The phase 3 MATINEE trial showed a 21% reduction in annualized moderate or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results